Long-term treatment with tamoxifen activates MAP kinase and mTOR pathway and enhances interaction between growth factor receptor and ERα in breast cancer cells.

被引：0
|
作者：
Fan, P
Yue, W
Wang, J
机构：
[1] Nanjing Med Univ, Nanjing, Peoples R China
[2] Univ Virginia, Charlottesville, VA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：84S / 84S
页数：1
相关论文
共 50 条
  • [41] TREATMENT WITH THE MTOR KINASE INHIBITOR CC-223 OVERCOMES RESISTANCE TO THE EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR ERLOTINIB IN NON-SMALL CELL LUNG CANCER CELLS
    Ekman, Simon
    Chan, Daniel
    Wynes, Murry W.
    Zhang, Zhiyong
    Rozeboom, Leslie
    Raymon, Heather
    Hege, Kristen
    Xu, Shuichan
    Filvaroff, Ellen
    Hirsch, Fred R.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1070 - S1070
  • [42] Enhancement of vascular endothelial growth factor release in long-term drug-treated breast cancer via transient receptor potential channel 5-Ca2+-hypoxia-inducible factor 1α pathway
    Zhu, Yifei
    Pan, Qiongxi
    Meng, Huan
    Jiang, Yueshui
    Mao, Aiqin
    Wang, Teng
    Hua, Dong
    Yao, Xiaoqiang
    Jin, Jian
    Ma, Xin
    PHARMACOLOGICAL RESEARCH, 2015, 93 : 36 - 42
  • [43] BAG-1 prevents stress-induced long-term growth inhibition in breast cancer cells via a chaperone-dependent pathway
    Townsend, PA
    Cutress, RI
    Sharp, A
    Brimmell, M
    Packham, G
    CANCER RESEARCH, 2003, 63 (14) : 4150 - 4157
  • [44] Involvement of lysophosphatidic acid (LPA) receptor-mediated signaling in breast cancer cell functions by long-term tamoxifen treatment under hypoxic and estrogen-deprived conditions
    Takai, Miwa
    Yamamoto, Mao
    Yashiro, Narumi
    Tsujiuchi, Toshifumi
    PATHOLOGY RESEARCH AND PRACTICE, 2024, 260
  • [45] Discovery of Promising Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), Estrogen Receptor (ER), and Phosphatidylinositol-3-kinase a (PI3Ka) for Personalized Breast Cancer Treatment
    Akinnusi, Precious A.
    Olubode, Samuel O.
    Adebesin, Ayomide O.
    Nana, Toluwani A.
    Shodehinde, Sidiqat A.
    CANCER INFORMATICS, 2022, 21
  • [46] Discovery of Promising Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), Estrogen Receptor (ER), and Phosphatidylinositol-3-kinase a (PI3Ka) for Personalized Breast Cancer Treatment
    Akinnusi, Precious A.
    Olubode, Samuel O.
    Adebesin, Ayomide O.
    Nana, Toluwani A.
    Shodehinde, Sidiqat A.
    CANCER INFORMATICS, 2022, 21
  • [47] Discovery of Promising Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), Estrogen Receptor (ER), and Phosphatidylinositol-3-kinase a (PI3Ka) for Personalized Breast Cancer Treatment
    Akinnusi, Precious A.
    Olubode, Samuel O.
    Adebesin, Ayomide O.
    Nana, Toluwani A.
    Shodehinde, Sidiqat A.
    CANCER INFORMATICS, 2022, 21
  • [48] Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells
    Kawai, H
    Li, HC
    Chun, P
    Avraham, S
    Avraham, HK
    ONCOGENE, 2002, 21 (50) : 7730 - 7739
  • [49] Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells
    Hideki Kawai
    Huchun Li
    Philip Chun
    Shalom Avraham
    Hava Karsenty Avraham
    Oncogene, 2002, 21 : 7730 - 7739
  • [50] Insulin-like growth factor binding protein-2 expression by ER plus ve breast cancer cells is regulated by PI-3 kinase pathway signaling
    Martin, Janet L.
    Philcox, Stephen J.
    Baxter, Robert C.
    CANCER RESEARCH, 2006, 66 (08)
12345